Neshima Medical
Life-saving Treatments for Severe Respiratory Diseases
Company Overview
Snapshot
Founded in April 2020 by Yan Ostrovski, Ramy Fishler, Avital Frenkel, and Josué Sznitman, Neshima Medical operates with 1–10 employees. The company has raised $250,000 across two funding rounds from three investors.
Business overview
Neshima Medical is a Health Tech & Life Sciences company focused on developing life-saving treatments for severe lung diseases. The company utilizes its patented LiFT™ foam-based delivery platform to enable deep and uniform therapeutic delivery to the alveoli, addressing limitations of traditional treatment methods. Neshima Medical's lead applications include regenerative cell therapy for COPD and an ICU-delivered antibiotic treatment for antimicrobial-resistant infections, targeting a B2B model within the healthcare sector.
Strategic signal
In April 2020, news reports highlighted Neshima Medical's pioneering foam therapy and novel technology as offering new hope for lung patients, particularly those with acute respiratory distress syndrome, including severe COVID-19 cases. This signals the company's potential to address critical unmet medical needs and validates its innovative approach to drug delivery in respiratory care.
Log in to access full profile ›Company Intelligence Q&A
- What is Neshima Medical's core technology?
- Neshima Medical develops life-saving treatments for severe lung diseases using LiFT™, a patented foam-based delivery platform designed for deep and uniform therapeutic delivery to the alveoli.
- When was Neshima Medical founded and by whom?
- Neshima Medical was founded in April 2020 by Yan Ostrovski, Ramy Fishler, Avital Frenkel, and Josué Sznitman.
- What are Neshima Medical's primary product applications?
- Neshima Medical's lead applications include a regenerative cell therapy for COPD and an ICU-delivered antibiotic treatment for antimicrobial-resistant infections.